Avantor to Distribute Quantum-Si’s Next-Generation Protein Sequencing™ Technology
Quantum-Si (Nasdaq: QSI) has entered into a distribution agreement with Avantor (NYSE: AVTR) for its Next-Generation Protein Sequencing (NGPS) technology portfolio in the U.S. and Canadian markets. The collaboration will enable broader access to QSI's proteomics solutions across various laboratory settings. The platform utilizes single-molecule sequencing technology for protein and biomarker identification, antibody characterization, protein barcoding, and post-translational modification analysis, supporting applications in drug discovery, diagnostics, and clinical research.
Quantum-Si (Nasdaq: QSI) ha stipulato un accordo di distribuzione con Avantor (NYSE: AVTR) per il suo portafoglio di tecnologia di Sequenziamento delle Proteine di Nuova Generazione (NGPS) nei mercati statunitensi e canadesi. Questa collaborazione permetterà un accesso più ampio alle soluzioni di proteomica di QSI in diversi contesti di laboratorio. La piattaforma utilizza la tecnologia di sequenziamento a singola molecola per l'identificazione delle proteine e dei biomarker, la caratterizzazione degli anticorpi, il codice a barre delle proteine e l'analisi delle modifiche post-traduzionali, supportando applicazioni nella scoperta di farmaci, diagnosi e ricerca clinica.
Quantum-Si (Nasdaq: QSI) ha firmado un acuerdo de distribución con Avantor (NYSE: AVTR) para su cartera de tecnología de Secuenciación de Proteínas de Nueva Generación (NGPS) en los mercados de EE. UU. y Canadá. La colaboración permitirá un acceso más amplio a las soluciones de proteómica de QSI en diversos entornos de laboratorio. La plataforma utiliza tecnología de secuenciación de moléculas únicas para la identificación de proteínas y biomarcadores, caracterización de anticuerpos, etiquetado de proteínas y análisis de modificaciones post-traducionales, apoyando aplicaciones en el descubrimiento de fármacos, diagnóstico e investigación clínica.
퀀텀-사이(Quantum-Si, Nasdaq: QSI)는 아반토르(Avantor, NYSE: AVTR)와 차세대 단백질 시퀀싱(NGPS) 기술 포트폴리오를 미국 및 캐나다 시장에 배포하기 위한 협약을 체결했습니다. 이 협력은 다양한 실험실 환경에서 QSI의 단백질체학 솔루션에 대한 더 넓은 접근을 가능하게 할 것입니다. 이 플랫폼은 단일 분자 시퀀싱 기술을 이용하여 단백질 및 바이오마커의 식별, 항체 특성화, 단백질 바코딩, 그리고 번역 후 수정 분석을 지원하며, 약물 발견, 진단 및 임상 연구 등에서 응용됩니다.
Quantum-Si (Nasdaq: QSI) a conclu un accord de distribution avec Avantor (NYSE: AVTR) pour son portefeuille de technologies de Séquençage des Protéines de Nouvelle Génération (NGPS) sur les marchés américain et canadien. Cette collaboration permettra un accès élargi aux solutions de protéomique de QSI dans divers environnements de laboratoire. La plateforme utilise la technologie de séquençage de molécules uniques pour l'identification des protéines et des biomarqueurs, la caractérisation des anticorps, le marquage des protéines et l'analyse des modifications post-traductionnelles, soutenant des applications dans la découverte de médicaments, le diagnostic et la recherche clinique.
Quantum-Si (Nasdaq: QSI) hat eine Vertriebsvereinbarung mit Avantor (NYSE: AVTR) für sein Portfolio an Technologien zur Proteinsequenzierung der nächsten Generation (NGPS) auf den Märkten in den USA und Kanada getroffen. Die Zusammenarbeit wird einen breiteren Zugang zu den Proteomik-Lösungen von QSI in verschiedenen Laborumgebungen ermöglichen. Die Plattform nutzt die Einzelmolekülsequenzierungstechnologie zur Identifizierung von Proteinen und Biomarkern, Charakterisierung von Antikörpern, Protein-Bencoding und Analyse von posttranslationalen Modifikationen und unterstützt Anwendungen in der Arzneimittelentdeckung, Diagnostik und klinischen Forschung.
- Strategic distribution partnership with Avantor expands market reach in US and Canada
- Access to Avantor's established distribution network and support infrastructure
- Potential for accelerated market penetration and sales growth
- None.
Insights
This distribution agreement with Avantor marks a significant strategic expansion for Quantum-Si's commercialization efforts. Avantor's extensive distribution network across the U.S. and Canada, serving over
The partnership addresses a critical market access challenge for QSI by leveraging Avantor's established relationships with research institutions, pharmaceutical companies and biotech firms. This should accelerate adoption of QSI's platform and potentially lead to faster revenue growth. However, the deal's financial terms and revenue-sharing structure aren't disclosed, making it difficult to quantify the immediate financial impact.
For a small-cap company like QSI (
Agreement Expands Access to Pioneering Proteomics Technology Across the
The distribution agreement enables Avantor to offer Quantum-Si’s protein sequencing technology to a broad range of laboratories focused on proteomics. Quantum-Si’s platform leverages single-molecule sequencing technology, with applications across protein and biomarker identification, antibody characterization, protein barcoding and post-translational modification analysis, to deliver unprecedented insights into protein structure and function, empowering scientists in fields like drug discovery, diagnostics, and clinical research.
“By making our portfolio available through Avantor, we are expanding the reach of our Next-Generation Protein Sequencing technology to a wider audience,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “We believe this agreement will allow us to rapidly scale delivery of our innovative solutions to more researchers, accelerating scientific discoveries and advancements in critical research areas.”
“Avantor’s strong presence in the
For more information on Quantum-Si’s technology and research applications, please visit The Protein Sequencing Company™ | Quantum-Si
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
About Avantor®
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, please visit www.avantorsciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241120216613/en/
Investor Contact
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media Contact
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What is the new distribution agreement between Quantum-Si (QSI) and Avantor?
What markets will Quantum-Si's (QSI) NGPS technology be distributed in?